EVENTS | VIEW CALENDAR
WCG and PCCTC announce new partnership to improve efficiency of oncology research reviews
PRINCETON, N.J. & NEW YORK—WIRB-Copernicus Group (WCG), a global provider of regulatory and ethical review services and software to support clinical research, and the Prostate Cancer Clinical Trials Consortium (PCCTC), a leading multicenter clinical research organization specializing in cutting-edge prostate cancer research, have formed a new partnership to enhance the quality and efficiency of the consortium’s research review process.
PCCTC joins many of the nation’s other prominent cancer research institutions in relying on WCG for the review of its cancer research protocols and related study documents. WCG Oncology, WCG’s cancer-focused division, is comprised of experts who specialize in oncological subspecialties and advise WCG’s three cancer-focused institutional review board (IRB) panels on the science behind cutting-edge therapies.
“We are delighted to provide PCCTC with the confidence that its research will be reviewed with the appropriate expertise and therapeutic focus, and in a timely and efficient manner. The consortium is doing sterling work in exploring cutting-edge science, and we are proud to facilitate the conduct of its important clinical research,” commented WCG Chairman and CEO Dr. Donald A. Deieso.
The partnership with WCG represents a significant change for PCCTC, which previously relied on its members’ local IRBs. That approach had resulted in several IRBs being required to approve the protocol, participant consent and other documents for a single study, leading to inconsistencies and unnecessary delays.
“The PCCTC is excited to collaborate with WCG to provide a more efficient and more thorough model for reviewing prostate cancer research,” said PCCTC CEO Jake Vinson. “We have conducted our first clinical study using WCG, and have already gained efficiencies by reducing administrative delays and eliminating the redundancy of multiple, uncoordinated reviews.”